JP2019536785A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536785A5
JP2019536785A5 JP2019528861A JP2019528861A JP2019536785A5 JP 2019536785 A5 JP2019536785 A5 JP 2019536785A5 JP 2019528861 A JP2019528861 A JP 2019528861A JP 2019528861 A JP2019528861 A JP 2019528861A JP 2019536785 A5 JP2019536785 A5 JP 2019536785A5
Authority
JP
Japan
Prior art keywords
methyl
pyrazole
fluorophenyl
alkyl
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019528861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536785A (ja
JP7373992B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/063774 external-priority patent/WO2018102453A1/en
Publication of JP2019536785A publication Critical patent/JP2019536785A/ja
Publication of JP2019536785A5 publication Critical patent/JP2019536785A5/ja
Application granted granted Critical
Publication of JP7373992B2 publication Critical patent/JP7373992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019528861A 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 Active JP7373992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428271P 2016-11-30 2016-11-30
US62/428,271 2016-11-30
PCT/US2017/063774 WO2018102453A1 (en) 2016-11-30 2017-11-29 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Publications (3)

Publication Number Publication Date
JP2019536785A JP2019536785A (ja) 2019-12-19
JP2019536785A5 true JP2019536785A5 (enExample) 2021-01-14
JP7373992B2 JP7373992B2 (ja) 2023-11-06

Family

ID=62241871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528861A Active JP7373992B2 (ja) 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法

Country Status (9)

Country Link
US (2) US11325903B2 (enExample)
EP (1) EP3548482A4 (enExample)
JP (1) JP7373992B2 (enExample)
CN (2) CN118930533A (enExample)
AU (1) AU2017366901B2 (enExample)
CA (1) CA3081983A1 (enExample)
IL (1) IL266930B2 (enExample)
MX (1) MX2019006299A (enExample)
WO (1) WO2018102453A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
JP2020513403A (ja) * 2016-11-30 2020-05-14 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
MX2019006299A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CA3142196A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
JP2022535228A (ja) * 2019-05-31 2022-08-05 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー チアゾリルピラゾールカルボン酸の製造方法およびそれらのための中間体
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CN116034106B (zh) * 2020-06-02 2025-11-04 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
EP4441050A1 (en) * 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
CN116678810A (zh) * 2022-02-23 2023-09-01 武汉市鼎华双雄生物科技有限责任公司 细胞增殖免疫荧光检测试剂盒及其应用
CN117003651B (zh) * 2023-09-28 2024-01-02 广东嘉博制药有限公司 一种l-肾上腺素的制备方法
WO2026152086A1 (en) 2025-01-10 2026-07-16 Bantam Pharmaceutical, Llc Pharmaceutical combinations of oma1 activators with bh3 mimetics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
TR200302047T4 (tr) 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
WO2003084544A2 (en) 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
EP1613614A2 (en) * 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
ES2423932T3 (es) 2007-08-27 2013-09-25 Basf Se Compuestos de pirazol para controlar plagas de invertebrados
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
US9409901B2 (en) 2012-10-22 2016-08-09 Bantam Pharmaceutical, Llc Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
ES2762947T3 (es) 2015-04-24 2020-05-26 Syngenta Participations Ag Derivados policíclicos con actividad plaguicida con anillos heterocíclicos de cinco miembros sustituidos con azufre
JP6707630B2 (ja) * 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
JP2020513403A (ja) * 2016-11-30 2020-05-14 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
MX2019006299A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
CA3142196A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Similar Documents

Publication Publication Date Title
JP2014506599A5 (enExample)
JP6561167B2 (ja) 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
JP6013375B2 (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
JP6326057B2 (ja) 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用
ES2629414T3 (es) Derivados de tiazol
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
JP2009524670A5 (enExample)
JP2016526576A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2020516671A5 (enExample)
JP2005538100A5 (enExample)
JP2012511588A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
US20230382889A1 (en) Compounds for inhibiting kif18a
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
JP2012512886A5 (enExample)
HRP20030961A2 (en) Novel pyrrole derivatives as pharmaceutical agents
JP2010513444A5 (enExample)
JP2017530185A5 (enExample)
JP2016513660A5 (enExample)
JP2012526774A (ja) アルドステロンシンターゼ阻害剤としてのアリールピリジン
JP2019536785A (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
RU2016141647A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
JP2012522766A5 (enExample)
JP2017529365A5 (enExample)